拉贝洛尔联合酚妥拉明对妊娠期高血压患者的疗效

doi:10.3760/cma.j.issn.1007-1245.2023.03.018

国际医药卫生导报 ›› 2023, Vol. 29 ›› Issue (3): 377-380.DOI: 10.3760/cma.j.issn.1007-1245.2023.03.018

拉贝洛尔联合酚妥拉明对妊娠期高血压患者的疗效

邵帅¹ 门贵香¹ 孙菊香¹ 洪善玲² 任国华²

¹临沂市人民医院产科六病区，临沂　276500；²临沂市人民医院产科二病区，临沂　276500

收稿日期:2022-09-28 出版日期:2023-02-01 发布日期:2023-03-03
通讯作者: 任国华，Email：r.guohua@163.com
基金资助:
山东省医药卫生科技发展计划项目（2019WS122）

Effect of labetalol combined with phentolamine on patients with gestational hypertension

Shao Shuai¹, Men Guixiang¹, Sun Juxiang¹, Hong Shanling², Ren Guohua²

¹Ward 6, Department of Obstetrics, Linyi People's Hospital, Linyi 276500, China; ²Ward 2, Department of Obstetrics, Linyi People's Hospital, Linyi 276500, China

Received:2022-09-28 Online:2023-02-01 Published:2023-03-03
Contact: Ren Guohua, Email: r.guohua@163.com
Supported by:
Health Science and Technology Development Program of Shandong Province (2019WS122)

摘要/Abstract

摘要：

目的　探讨拉贝洛尔联合酚妥拉明对妊娠期高血压患者妊娠结局及爱帕琳肽（Apelin）、血栓调节蛋白（PTM）水平的影响。方法　本研究为随机对照试验。选择2019年2月至2022年2月临沂市人民医院收治的86例妊娠期高血压患者为研究对象，以随机数字表法分为观察组（43例）与对照组（43例）。对照组年龄（29.12±3.93）岁，孕周（29.63±4.12）周；观察组年龄（28.23±3.19）岁，孕周（31.01±4.13）周。对照组采用酚妥拉明治疗，观察组在对照组的基础上给予拉贝洛尔治疗，两组均持续治疗7 d后观察效果。对比两组患者的临床疗效及不良妊娠结局，比较治疗前后Apelin、PTM水平。统计学方法采用χ²检验、独立样本t检验、配对t检验。结果　观察组患者的临床总有效率高于对照组［93.02%（40/43）比76.74%（33/43）］，两组比较差异有统计学意义（χ²=4.440，P=0.035）。治疗前，两组患者的Apelin、PTM水平比较差异均无统计学意义（均P>0.05）；治疗后，两组的Apelin、PTM均降低，且观察组患者的Apelin、PTM水平均低于对照组［（38.52±5.12）ng/L比（43.25±6.25）ng/L、（201.32±18.25）ng/L比（281.51±19.25）ng/L］，差异均有统计学意义（t=3.839、19.824，均P<0.001）。观察组不良妊娠结局总发生率低于对照组［4.65%（2/43）比20.93%（9/45）］，差异有统计学意义（χ²=5.108，P=0.024）。结论　拉贝洛尔联合酚妥拉明治疗妊娠期高血压患者，有利于提高治疗效果，降低Apelin、PTM水平及不良妊娠结局发生率。

关键词:

妊娠期高血压, 拉贝洛尔, 酚妥拉明, 爱帕琳肽, 不良妊娠结局

Abstract:

Objective　To investigate the effects of labetalol combined with phentolamine on the pregnancy outcomes and levels of Apelin and thrombomodulin (PTM) in patients with gestational hypertension. Methods　It was a randomized controlled trial. A total of 86 patients with gestational hypertension admitted to Linyi People's Hospital from February 2019 to February 2022 were selected as the research objects. They were divided into an observation group (43 cases) and a control group (43 cases) by the random number table method. The age of the control group was (29.12±3.93) years old and the gestational age was (29.63±4.12) weeks; the age of the observation group was (28.23±3.19) years old and the gestational age was (31.01±4.13) weeks. The control group was treated with phentolamine, and the observation group was treated with labetalol on the basis of the control group. The effects of both groups were observed after 7 days of continuous treatment. The clinical effects and adverse pregnancy outcomes of the two groups were compared, and the levels of Apelin and PTM before and after treatment were compared. χ² test, independent sample t test, and paired t test were used. Results　The clinical effective rate of the observation group was higher than that of the control group [93.02% (40/43) vs. 76.74% (33/43)], with a statistically significant difference between the two groups (χ²=4.440, P=0.035). Before treatment, there were no statistically significant differences in the levels of Apelin and PTM between the two groups (both P>0.05). After treatment, the levels of Apelin and PTM decreased in both groups, and the levels of Apelin and PTM in the observation group were lower than those in the control group [(38.52±5.12) ng/L vs. (43.25±6.25) ng/L, (201.32±18.25) ng/L vs. (281.51±19.25) ng/L], with statistically significant differences (t=3.839 and 19.824; both P<0.001). The incidence of adverse pregnancy outcomes in the observation group was lower than that in the control group [4.65% (2/43) vs. 20.93% (9/45)] (χ²=5.108, P=0.024). Conclusion　Labetalol combined with phentolamine can improve the therapeutic effect in patients with gestational hypertension, reduce the levels of Apelin and PTM, and reduce the incidence of adverse pregnancy outcomes.

Key words:

Gestational hypertension, Labetalol, Phentolamine, Apelin, Adverse pregnancy outcomes

邵帅门贵香孙菊香洪善玲任国华.

拉贝洛尔联合酚妥拉明对妊娠期高血压患者的疗效 [J]. 国际医药卫生导报, 2023, 29(3): 377-380.

Shao Shuai, Men Guixiang, Sun Juxiang, Hong Shanling, Ren Guohua.

Effect of labetalol combined with phentolamine on patients with gestational hypertension [J]. International Medicine and Health Guidance News, 2023, 29(3): 377-380.

参考文献

[1] 李梅,李琼阁,王金萍,等. 妊娠期高血压疾病防治循证意见专家咨询与分析[J]. 国际医药卫生导报,2020,26(10):1342-1346. DOI:10.3760/cma.j.issn.1007-1245.2020. 10.003.
[2] Takahashi K, Nishijima K, Yamaguchi M, et al. Noninvasive positive-pressure ventilation in pregnancy to treat acute pulmonary edema induced by tocolytic agents: a case report[J]. J Med Case Rep, 2021, 15(1): 126. DOI: 10.1186/s13256-021-02704-w.
[3] Magro-Malosso ER, Saccone G, Di Tommaso M, et al. Exercise during pregnancy and risk of gestational hypertensive disorders: a systematic review and meta-analysis[J]. Acta Obstet Gynecol Scand, 2017, 96(8): 921-931. DOI: 10.1111/aogs.13151.
[4] Waugh J, Hooper R, Lamb E, et al. Spot protein-creatinine ratio and spot albumin-creatinine ratio in the assessment of pre-eclampsia: a diagnostic accuracy study with decision-analytic model-based economic evaluation and acceptability analysis[J]. Health Technol Assess, 2017, 21(61): 1-90. DOI: 10.3310/hta21610.
[5] Adebayo JA, Nwafor JI, Lawani LO, et al. Efficacy of nPTMedipine versus hydralazine in the management of severe hypertension in pregnancy: a randomised controlled trial[J]. Niger Postgrad Med J, 2020, 27(4): 317-324. DOI: 10.4103/npmj.npmj_275_20.
[6] 范光琴, 陈晓燕, 张晓蓉. 不同治疗方式对早发型重度子痫前期的治疗效果分析[J]. 卫生职业教育, 2020, 38(23):146-148.
[7] 罗琼,王晓华. 拉贝洛尔联合酚妥拉明治疗妊娠期高血压疾病患者的疗效及对胎盘血管内皮生长因子的影响[J]. 中国妇幼保健,2020,35(3):415-418. DOI:10.19829/j.zgfybj- issn.1001-4411.2020.03.009.
[8] Ives CW, Sinkey R, Rajapreyar I, et al. Preeclampsia-pathophysiology and clinical presentations: JACC state-of-the-art review[J]. J Am Coll Cardiol, 2020, 76(14): 1690-1702. DOI: 10.1016/j.jacc.2020.08.014.
[9] Giri H, Cai X, Panicker SR, et al. Thrombomodulin regulation of mitogen-activated protein kinases[J]. Int J Mol Sci, 2019, 20(8): 1851. DOI: 10.3390/ijms20081851.
[10] 杨孜, 张为远. 妊娠期高血压诊治指南(2015)[J]. 中华妇产科杂志, 2015, 5(10): 8. DOI: 10.3760/cma.j.issn.0529- 567x.2015.10.001.
[11] Rana S, Lemoine E, Granger JP, et al. Preeclampsia: pathophysiology, challenges, and perspectives[J]. Circ Res, 2019, 124(7): 1094-1112. DOI: 10.1161/CIRCRESAHA. 118.313276.
[12] Dikalova AE, Pandey A, Xiao L, et al. Mitochondrial deacetylase Sirt3 reduces vascular dysfunction and hypertension while Sirt3 depletion in essential hypertension is linked to vascular inflammation and oxidative stress[J]. Circ Res, 2020, 126(4): 439-452. DOI: 10.1161/CIRCRESAHA.119.315767.
[13] Turbeville HR, Sasser JM. Preeclampsia beyond pregnancy: long-term consequences for mother and child[J]. Am J Physiol Renal Physiol, 2020, 318(6): F1315-F1326. DOI: 10.1152/ajprenal.00071.2020.
[14] Jena MK, Sharma NR, Petitt M, et al. Pathogenesis of preeclampsia and therapeutic approaches targeting the placenta[J]. Biomolecules, 2020, 10(6): 953-966. DOI: 10.3390/biom10060953.
[15] Ishiyama N, Nishino M, Murakami M. Relationships between blood rheology and age, body mass index, blood cell count, fibrinogen, and lipids in healthy subjects[J]. Clin Hemorheol Microcirc, 2019, 34(3): 401-410.
[16] Sridharan K, Sequeira RP. Drugs for treating severe hypertension in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials[J]. Br J Clin Pharmacol, 2018, 84(9): 1906-1916. DOI:10.1111/bcp.13649.
[17] Sharma KJ, Greene N, Kilpatrick SJ. Oral labetalol compared to oral nPTMedipine for postpartum hypertension: a randomized controlled trial[J]. Hypertens Pregnancy, 2017, 36(1): 44-47. DOI: 10.1111/1471-0528. 12737.
[18] Easterling T, Mundle S, Bracken H, et al. Oral antihypertensive regimens (nPTMedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial[J]. Lancet, 2019, 394(10203): 1011-1021. DOI: 10.1016/S0140-6736(19)31282-6.
[19] Coghlan JG, Channick R, Chin K, et al. Targeting the prostacyclin pathway with Selexipag in patients with pulmonary arterial hypertension receiving double combination therapy: insights from the randomized controlled GRIPHON study[J]. Am J Cardiovasc Drugs, 2018, 18(1): 37-47. DOI: 10.1007/s40256-017-0262-z.
[20] Sano T, Terai Y, Daimon A, et al. Recombinant human soluble thrombomodulin as an anticoagulation therapy improves recurrent miscarriage and fetal growth restriction due to placental insufficiency - the leading cause of preeclampsia[J]. Placenta, 2018, 12(65): 1-6. DOI: 10.1016/j.placenta.2018.03.006.
[21] 陈鹤,郭伟. 拉贝洛尔联合酚妥拉明治疗对妊娠期高血压患者的影响[J]. 临床研究,2022,30(7):77-80. DOI:10.12385/j.issn.2096-1278(2022)07-0077-04.
[22] Huang T, Bedford HM, Rashid S, et al. Modified multiple marker aneuploidy screening as a primary screening test for preeclampsia[J]. BMC Pregnancy Childbirth, 2022, 22(1): 190. DOI: 10.1186/s12884-022-04514-4.
[23] Suresh SC, Rana S. Real-world use of biomarkers in management of hypertension during pregnancy: adjunct to clinical care[J]. Hypertension, 2021, 77(2): 472-474. DOI: 10.1161/HYPERTENSIONAHA.120.16422.
[24] Magee LA, von Dadelszen P. Treatment for mild chronic hypertension during pregnancy[J]. N Engl J Med, 2022, 387(7): 664. DOI: 10.1056/NEJMc2207889.
[25] Johnson S, Liu B, Kalafat E, et al. Maternal and perinatal outcomes of white coat hypertension during pregnancy: a systematic review and meta-analysis[J]. Hypertension, 2020, 76(1): 157-166. DOI: 10.1161/HYPERTENSIONAHA.119.14627.
[26] Garovic VD, White WM, Vaughan L, et al. Incidence and long-term outcomes of hypertensive disorders of pregnancy[J]. J Am Coll Cardiol, 2020, 75(18): 2323-2334. DOI:10.1016/j.jacc.2020.03.028.
[27] Stepan H, Hund M, Andraczek T. Combining biomarkers to predict pregnancy complications and redefine preeclampsia: the angiogenic-placental syndrome[J]. Hypertension, 2020, 75(4): 918-926. DOI:10.1161/HYPERTENSIONAHA.119.13763.
[28] Brown MA, Magee LA, Kenny LC, et al. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice[J]. Hypertension, 2018, 72(1): 24-43. DOI:10.1161/HYPERTENSIONAHA.117.10803.
[29] Kriechbaum SD, Rudolph F, Wiedenroth CB, et al. Pregnancy-associated plasma protein A - a new indicator of pulmonary vascular remodeling in chronic thromboembolic pulmonary hypertension[J]. Respir Res, 2020, 21(1): 204. DOI:10.1186/s12931-020-01472-3.
[30] 程华英,胡娅萍,郑璇,等. 妊娠期高血压疾病孕妇血清AGEs、TGF-β1、PAPP-A及RBP4变化及临床意义[J]. 分子诊断与治疗杂志,2022,14(4):631-634,638. DOI:10.3969/j.issn.1674-6929.2022.04.024.

拉贝洛尔联合酚妥拉明对妊娠期高血压患者的疗效

Effect of labetalol combined with phentolamine on patients with gestational hypertension

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 1

编辑推荐

Metrics